STING1 and neoplasm: Future in vivo studies are warranted to evaluate the therapeutic efficacy of STING-stimulated DC vaccines, the durability of induced T cell responses, and potential synergistic effects with checkpoint inhibitors or tumor-associated antigen delivery.